Brief: Cognition Therapeutics Reports Q3 Financial Results, Provides Business Update
14/11/2022 18:11
Nov 14 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
* COGNITION THERAPEUTICS INC - SHINE ALZHEIMER'S TRIAL
EXPANDS TO
EUROPEAN SITES
* COGNITION THERAPEUTICS INC - CASH RUNWAY EXTENDED INTO
FIRST
HALF OF 2024, INCLUSIVE OF A $2.14 MILLION ADDITIONAL NIA GRANT
AWARDED FOR SEQUEL STUDY
* COGNITION THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AT
SEPTEMBER 30, 2022 WERE ABOUT $46.6 MILLION.
* COGNITION THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.29
Source text for Eikon: ID:nGNX9m14Zj
Further company coverage: CGTX.O
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB